200 related articles for article (PubMed ID: 31532069)
41. Tau Modulates mRNA Transcription, Alternative Polyadenylation Profiles of hnRNPs, Chromatin Remodeling and Spliceosome Complexes.
Montalbano M; Jaworski E; Garcia S; Ellsworth A; McAllen S; Routh A; Kayed R
Front Mol Neurosci; 2021; 14():742790. PubMed ID: 34924950
[TBL] [Abstract][Full Text] [Related]
42. Generation of a human induced pluripotent stem cell-based model for tauopathies combining three microtubule-associated protein TAU mutations which displays several phenotypes linked to neurodegeneration.
García-León JA; Cabrera-Socorro A; Eggermont K; Swijsen A; Terryn J; Fazal R; Nami F; Ordovás L; Quiles A; Lluis F; Serneels L; Wierda K; Sierksma A; Kreir M; Pestana F; Van Damme P; De Strooper B; Thorrez L; Ebneth A; Verfaillie CM
Alzheimers Dement; 2018 Oct; 14(10):1261-1280. PubMed ID: 30036493
[TBL] [Abstract][Full Text] [Related]
43. Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease.
Eftekharzadeh B; Daigle JG; Kapinos LE; Coyne A; Schiantarelli J; Carlomagno Y; Cook C; Miller SJ; Dujardin S; Amaral AS; Grima JC; Bennett RE; Tepper K; DeTure M; Vanderburg CR; Corjuc BT; DeVos SL; Gonzalez JA; Chew J; Vidensky S; Gage FH; Mertens J; Troncoso J; Mandelkow E; Salvatella X; Lim RYH; Petrucelli L; Wegmann S; Rothstein JD; Hyman BT
Neuron; 2018 Sep; 99(5):925-940.e7. PubMed ID: 30189209
[TBL] [Abstract][Full Text] [Related]
44. Isomerization and Oligomerization of Truncated and Mutated Tau Forms by FKBP52 are Independent Processes.
Kamah A; Cantrelle FX; Huvent I; Giustiniani J; Guillemeau K; Byrne C; Jacquot Y; Landrieu I; Baulieu EE; Smet C; Chambraud B; Lippens G
J Mol Biol; 2016 Mar; 428(6):1080-1090. PubMed ID: 26903089
[TBL] [Abstract][Full Text] [Related]
45. Proteolytic processing of tau.
Wang Y; Garg S; Mandelkow EM; Mandelkow E
Biochem Soc Trans; 2010 Aug; 38(4):955-61. PubMed ID: 20658984
[TBL] [Abstract][Full Text] [Related]
46. Characterization of the RNA-binding protein Musashi1 in zebrafish.
Shibata S; Umei M; Kawahara H; Yano M; Makino S; Okano H
Brain Res; 2012 Jun; 1462():162-73. PubMed ID: 22429745
[TBL] [Abstract][Full Text] [Related]
47. Alpha-synuclein and tau: teammates in neurodegeneration?
Moussaud S; Jones DR; Moussaud-Lamodière EL; Delenclos M; Ross OA; McLean PJ
Mol Neurodegener; 2014 Oct; 9():43. PubMed ID: 25352339
[TBL] [Abstract][Full Text] [Related]
48. Granular tau oligomers as intermediates of tau filaments.
Maeda S; Sahara N; Saito Y; Murayama M; Yoshiike Y; Kim H; Miyasaka T; Murayama S; Ikai A; Takashima A
Biochemistry; 2007 Mar; 46(12):3856-61. PubMed ID: 17338548
[TBL] [Abstract][Full Text] [Related]
49. Hsp90 activator Aha1 drives production of pathological tau aggregates.
Shelton LB; Baker JD; Zheng D; Sullivan LE; Solanki PK; Webster JM; Sun Z; Sabbagh JJ; Nordhues BA; Koren J; Ghosh S; Blagg BSJ; Blair LJ; Dickey CA
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9707-9712. PubMed ID: 28827321
[TBL] [Abstract][Full Text] [Related]
50. Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.
David DC; Ittner LM; Gehrig P; Nergenau D; Shepherd C; Halliday G; Götz J
Proteomics; 2006 Dec; 6(24):6566-77. PubMed ID: 17111439
[TBL] [Abstract][Full Text] [Related]
51. Tau oligomerization: a role for tau aggregation intermediates linked to neurodegeneration.
Sahara N; Maeda S; Takashima A
Curr Alzheimer Res; 2008 Dec; 5(6):591-8. PubMed ID: 19075586
[TBL] [Abstract][Full Text] [Related]
52. Assembly of filamentous tau aggregates in human neuronal cells.
Ko LW; Rush T; Sahara N; Kersh JS; Easson C; Deture M; Lin WL; Connor YD; Yen SH
J Alzheimers Dis; 2004 Dec; 6(6):605-22; discussion 673-81. PubMed ID: 15665401
[TBL] [Abstract][Full Text] [Related]
53. Female hippocampus vulnerability to environmental stress, a precipitating factor in Tau aggregation pathology.
Sotiropoulos I; Silva J; Kimura T; Rodrigues AJ; Costa P; Almeida OF; Sousa N; Takashima A
J Alzheimers Dis; 2015; 43(3):763-74. PubMed ID: 25159665
[TBL] [Abstract][Full Text] [Related]
54. Probable participation of 14-3-3 in tau protein oligomerization and aggregation.
Sluchanko NN; Gusev NB
J Alzheimers Dis; 2011; 27(3):467-76. PubMed ID: 21876254
[TBL] [Abstract][Full Text] [Related]
55. 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.
Sydow A; Mandelkow EM
Neurodegener Dis; 2010; 7(1-3):28-31. PubMed ID: 20160454
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of tau aggregation in cell models of tauopathy.
Khlistunova I; Pickhardt M; Biernat J; Wang Y; Mandelkow EM; Mandelkow E
Curr Alzheimer Res; 2007 Dec; 4(5):544-6. PubMed ID: 18220518
[TBL] [Abstract][Full Text] [Related]
57. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.
Brandt R; Hundelt M; Shahani N
Biochim Biophys Acta; 2005 Jan; 1739(2-3):331-54. PubMed ID: 15615650
[TBL] [Abstract][Full Text] [Related]
58. Human cyclophilin 40 unravels neurotoxic amyloids.
Baker JD; Shelton LB; Zheng D; Favretto F; Nordhues BA; Darling A; Sullivan LE; Sun Z; Solanki PK; Martin MD; Suntharalingam A; Sabbagh JJ; Becker S; Mandelkow E; Uversky VN; Zweckstetter M; Dickey CA; Koren J; Blair LJ
PLoS Biol; 2017 Jun; 15(6):e2001336. PubMed ID: 28654636
[TBL] [Abstract][Full Text] [Related]
59. The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.
Deger JM; Gerson JE; Kayed R
Aging Cell; 2015 Oct; 14(5):715-24. PubMed ID: 26053162
[TBL] [Abstract][Full Text] [Related]
60. Synergy and antagonism of macroautophagy and chaperone-mediated autophagy in a cell model of pathological tau aggregation.
Wang Y; Martinez-Vicente M; Krüger U; Kaushik S; Wong E; Mandelkow EM; Cuervo AM; Mandelkow E
Autophagy; 2010 Jan; 6(1):182-3. PubMed ID: 20023429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
